Life-prolonging drug ‘too expensive’ for NHS breast cancer patients

Breast cancer patients in England will be barred from a life-prolonging drug after the country’s socialized healthcare system deemed it ‘too expensive’.

A drug that would prolong the lives of people with advanced breast cancer will not be made available to many patients in England after the country’s socialized healthcare system deemed it ‘too expensive’.

While the drug known as Trodelvy will be made available to the public in Scotland, which runs its own public healthcare system, England’s National Institute for Health and Care Excellence (NICE) has decided it would be best that women south of the border cannot benefit from the drug themselves, saying it is not “a cost-effective use of [National Health Service] Resources”.

According to a report by The telegraphAround 650 women in England are said to have benefited from taking the drug, with one charity describing the decision as a ‘devastating blow’.

“Evidence shows that Trodelvy can increase the time before a patient’s disease progresses and, importantly, how long they live compared to chemotherapy treatment,” said Delyth Morgan, who is chief executive of the Breast Cancer Now charity.

The head of the charity also took aim at the public health system’s mishandling of cancer cases, saying women deserved access to such a drug.

“These women, who already face extremely grim prognoses and limited treatment options, deserve to be able to benefit from this new treatment option,” said the CEO.

Although apparently hugely popular with the general public, the UK’s socialized healthcare system has a relatively poor record of effectively treating cancer cases.

Waiting times for on-ward treatment are nowhere near where the UK government thinks they should be, with 98 per cent of NHS areas in England falling short of their waiting time targets for January by This year.

Meanwhile, survival rates for cancer patients within the system are low compared to other first-world counterparts, with fewer than three in five colon cancer patients surviving for five or more years after the onset of cancer. diagnosis in Britain, compared to more than two-thirds in Canada and 70.8% in Australia.

This example appears to be representative of other variants of the disease, with a London School of Hygiene and Tropical Medicine study of cancer survival rates in 28 different nation states consistently finding patients in the UK with lower than the average.

However, it’s not just people with cancer the NHS is failing, with a review of maternal health care in a section of the socialized system finding that 300 babies died unnecessarily due to an unhealthy obsession with births natural.

“The system had many opportunities to wake up and realize there was a problem with that trust,” said senior midwife Donna Ockenden, who led the official investigation into the scandal. , also commenting that she was “shocked and saddened” by her findings.

“There have been a number of occasions where families have tried to be heard for many years and have been silenced or ignored,” she said.

“We saw families that were separated, families where relationships were broken, cases of trauma and PTSD that lingered for years after the event and terrible, terrible sadness.”

Follow Peter Caddle on Twitter: @Peter_Caddle
Follow Breitbart London on Facebook: Breitbart London


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button